BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth ConferenceGlobeNewsWire • 08/03/22
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid WithdrawalGlobeNewsWire • 08/01/22
BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022GlobeNewsWire • 07/26/22
BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great AssetSeeking Alpha • 07/19/22
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/20/22
BioXcel Therapeutics (BTAI) CEO, Vimal Mehta on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational HighlightsGlobeNewsWire • 05/09/22
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer's DiseaseGlobeNewsWire • 05/03/22
BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022GlobeNewsWire • 04/26/22
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in OncologyGlobeNewsWire • 04/19/22
BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment AuthorityGlobeNewsWire • 04/19/22
BioXcel says the FDA approved its therapy for adults with schizophrenia or bipolar disorderMarket Watch • 04/06/22
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in AdultsGlobeNewsWire • 04/06/22